Skin & Longevity

GHK-Cu, Epithalon, Glow and Klow blends and other anti-aging and longevity peptides.

What the New Federal Peptide Framework Means for Pharmacists and Patients

What the New Federal Peptide Framework Means for Pharmacists and Patients

The U.S. Department of Health and Human Services has issued an interim framework that lets state-licensed pharmacies compound several specific peptides while formal rulemaking continues. The FDA's Pharmacy Compounding Advisory Committee is also scheduled to review five more peptides by the end of February. Industry leaders say the policy is shifting how pharmacists and prescribers think about these therapies, but they stress that enforcement discretion is not FDA approval and that clinical safety data remains limited. For pharmacists, the message is clear: rely on professional judgment, stay current, and evaluate each patient carefully.

Draft HHS Peptide Policy Puts Pharmacists Between Access and Caution

Draft HHS Peptide Policy Puts Pharmacists Between Access and Caution

As the comment period closes on a Department of Health and Human Services draft policy, pharmacy leaders are being urged to wait for the final version from the FDA before changing operations. The draft would let state-licensed 503A pharmacies compound six unapproved peptides, including BPC-157 and TB-500, without federal enforcement action. Supporters say the shift could bring patients into regulated channels and away from gray-market sellers. FDA reviewers, the American Medical Association, and the American Pharmacists Association have raised safety and evidence concerns. Pharmacists weighing entry into peptide compounding should verify ingredient sourcing, documentation, adverse event reporting, and state rules while the policy remains in draft form.

Gray-Market Peptides Are Everywhere. Here's What You Should Know.

Gray-Market Peptides Are Everywhere. Here's What You Should Know.

Injectable peptides have moved from quiet laboratory research into wellness clinics, influencer videos, and biohacker forums. Many are sold through gray-market supply chains with little human safety data. Health Secretary Kennedy has pushed to restore access to peptides the FDA had restricted, and an FDA committee he reshaped has recommended letting six of them back into legal production through compounding pharmacies. Critics, including FDA scientists, warn that the products are often untested and inconsistently made. This guide walks through what peptides are, why the products are so popular, the risks researchers have flagged, and how the regulatory fight developed.

Low T in Army Men, GLP-1 Blood Pressure Data and Retatrutide Side Effects Make the News

Low T in Army Men, GLP-1 Blood Pressure Data and Retatrutide Side Effects Make the News

A new round of health research points to a wide range of hormone and metabolic findings. Roughly a quarter of active-duty U.S. Army men had a morning testosterone level under 300 ng/dL, a common cutoff for low testosterone. A CDC report found nearly half of American women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of them took prescription medication for those symptoms. Separate studies linked GLP-1 drugs to blood pressure drops and early anti-aging signals. Novo Nordisk reported weight-loss results in women, and Walmart said it will cover over 250 prescription drugs, including some GLP-1 drugs for diabetes, for employees in 2027. An analysis of Reddit posts also cataloged side effects reported by users of the unapproved weight-loss drug retatrutide.